Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review

Felton, JL; Griffin, KJ; Oram, RA; Speake, C; Long, SA; Onengut-Gumuscu, S; Rich, SS; Monaco, GSF; Evans-Molina, C; DiMeglio, LA; Ismail, HM; Steck, AK; Dabelea, D; Johnson, RK; Urazbayeva, M; Gitelman, S; Wentworth, JM; Redondo, MJ; Sims, EK

Author(s): Felton, JL; Griffin, KJ; Oram, RA; Speake, C; Long, SA; Onengut-Gumuscu, S; Rich, SS; Monaco, GSF; Evans-Molina, C; DiMeglio, LA; Ismail, HM; Steck, AK; Dabelea, D; Johnson, RK; Urazbayeva, M; Gitelman, S; Wentworth, JM; Redondo, MJ; Sims, EK;
Details: Publication Year 2023-10-05,Volume 3,Issue #1,Page 130
Journal Title: Communications Medicine
Abstract: BACKGROUND: Type 1 diabetes (T1D) results from immune-mediated destruction of insulin-producing beta cells. Prevention efforts have focused on immune modulation and supporting beta cell health before or around diagnosis; however, heterogeneity in disease progression and therapy response has limited translation to clinical practice, highlighting the need for precision medicine approaches to T1D disease modification. METHODS: To understand the state of knowledge in this area, we performed a systematic review of randomized-controlled trials with ≥50 participants cataloged in PubMed or Embase from the past 25 years testing T1D disease-modifying therapies and/or identifying features linked to treatment response, analyzing bias using a Cochrane-risk-of-bias instrument. RESULTS: We identify and summarize 75 manuscripts, 15 describing 11 prevention trials for individuals with increased risk for T1D, and 60 describing treatments aimed at preventing beta cell loss at disease onset. Seventeen interventions, mostly immunotherapies, show benefit compared to placebo (only two prior to T1D onset). Fifty-seven studies employ precision analyses to assess features linked to treatment response. Age, beta cell function measures, and immune phenotypes are most frequently tested. However, analyses are typically not prespecified, with inconsistent methods of reporting, and tend to report positive findings. CONCLUSIONS: While the quality of prevention and intervention trials is overall high, the low quality of precision analyses makes it difficult to draw meaningful conclusions that inform clinical practice. To facilitate precision medicine approaches to T1D prevention, considerations for future precision studies include the incorporation of uniform outcome measures, reproducible biomarkers, and prespecified, fully powered precision analyses into future trial design.; Type 1 diabetes (T1D) is a condition that results from the destruction of a type of cell in the pancreas that produces the hormone insulin, leading to lifelong dependence on insulin injections. T1D prevention remains a challenging goal, largely due to the immense variability in disease processes and progression. Therapies tested to date in medical research settings (clinical trials) work only in a subset of individuals, highlighting the need for more tailored prevention approaches. We reviewed clinical trials of therapies targeting the disease process in T1D. While the overall quality of trials was high, studies testing individual features affecting responses to treatments were low. This review reveals an important need to carefully plan high-quality analyses of features that affect treatment response in T1D, to ensure that tailored approaches may one day be applied to clinical practice.; eng
Research Division(s): Population Health And Immunity
PubMed ID: 37794169
Publisher's Version: https://doi.org/10.1038/s43856-023-00357-y
Open Access at Publisher's Site: https://doi.org/10.1038/s43856-023-00357-y
Terms of Use/Rights Notice: Refer to copyright notice on published article.
Documents: s43856-023-00357-y.pdf - (1.77MB, application/pdf)

Creation Date: 2023-11-15 05:00:06

Last Modified: 2023-11-15 05:19:57